Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of RO5479599 alone or with cetuximab/erlotinib in HER3-positive advanced solid tumors
NL-OMON41335Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of lumretuzumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more (4 arms), sponsored by Roche. Primary endpoints: Safety profile of RO5479599 monotherapy, Pharmacokinetics of RO5479599 monotherapy and 3 more. Started Dec 2011; status: active, not recruiting.
02
Drugs
lumretuzumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON41335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41335.